President, Division Head for Clinical Development & Supply and Former Interim Chief Financial Officer · Catalent, Inc. (CLT)

Ricky Hopson

FY2023 is the first fiscal year CompBrief holds for Ricky Hopson as a named executive officer of Catalent; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$972,307

Salary $380,000Stock awards $245,150

7th of 7 named executive officers at Catalent by FY2023 total.

7 named officers on file for Catalent, FY2023

Ricky Hopson’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 4 equity grants, each cited to its filing
  • CLT’s disclosed peer group of 15 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Catalent’s whole pay program stands against its peers

  • Catalent’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on CLT→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed December 15, 2023 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Ricky Hopson’s full pay file as a PDF — free

More than this page: up to 10 years of Ricky’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Ricky Hopson compensation by year

Catalent Summary Compensation Table · the one fiscal year held
In US dollars, as Catalent reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023
Salary$380,000
Bonus$0
Stock awards$245,150
Option awards$105,032
Non-equity incentive$139,500
Pension and deferred compensation$0
All other$102,625
Total$972,307

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Catalent, Inc. DEF 14A filed December 15, 2023, accession 0001193125-23-295996, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Catalent, Inc. filed document, accession 0001193125-23-295996. Every figure is read from that document and cited to the page and table it appears in. Filed December 15, 2023.

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
RSU3,432$148,812—
RSU747$32,390—
RSU651$28,227—
RSU563$24,412—
RSU496$21,507—
PSU443$19,208—
PSU407$17,648—
PSU321$13,919—
PSU310$13,442—
Option1,924—$113.00
Option1,529—$88.10
Option1,218—$54.94

Per the Outstanding Equity Awards at Fiscal Year-End table in Catalent, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it. The 12 largest of 13 award rows shown.

Insider transactions since the last proxy

14 Form 4 lines since the FY2023 proxy (filed December 15, 2023)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2024-12-18Disposition to the issuer derivative—3,055—0
2024-12-18Disposition to the issuer derivative—2,828—0
2024-12-18Disposition to the issuer derivative—10,669—0
2024-12-18Grant or award—10,722$0.0010,722
2024-12-18Disposition to the issuer derivative—1,550—0
2024-12-18Disposition to the issuer derivative—2,622—0
2024-12-18Disposition to the issuer derivative—3,650—0
2024-12-18Disposition to the issuer derivative—2,565—0

The 8 most recent of 14 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Catalent’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Alessandro MaselliPresident and Chief Executive Officer$6,583,672
John ChiminskiFormer Executive Chair$4,807,767
Manja BoermanFormer President, Division Head for Biomodalities$3,979,888
Aristippos GennadiosGroup President, Pharma and Consumer Health$3,799,557
Thomas CastellanoFormer Senior Vice President and Chief Financial Officer$2,729,983
Steven FasmanFormer Executive Vice President & Chief Administrative Officer$2,310,299
Ricky Hopson · this pagePresident, Division Head for Clinical Development & Supply and Former Interim Chief Financial Officer$972,307

The full Catalent compensation record

free company brief

This page is one person within Catalent's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Catalent's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Ricky Hopson's compensation dossier · One-time report. No refunds.